[go: up one dir, main page]

MX2017010698A - Metodos y composiciones para chlamydia atenuada como vacuna y vector. - Google Patents

Metodos y composiciones para chlamydia atenuada como vacuna y vector.

Info

Publication number
MX2017010698A
MX2017010698A MX2017010698A MX2017010698A MX2017010698A MX 2017010698 A MX2017010698 A MX 2017010698A MX 2017010698 A MX2017010698 A MX 2017010698A MX 2017010698 A MX2017010698 A MX 2017010698A MX 2017010698 A MX2017010698 A MX 2017010698A
Authority
MX
Mexico
Prior art keywords
substitution
compositions
methods
vaccine
vector
Prior art date
Application number
MX2017010698A
Other languages
English (en)
Inventor
Zhong Guangming
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2017010698A publication Critical patent/MX2017010698A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee organismos de Chlamydia y composiciones y métodos de uso en el tratamiento/prevención de infección por Chlamydia en un sujeto, para producer una respuesta inmune en un sujeto y para uso como vectores; en un aspecto, la presente invención provee una célula de Chlamydia trachomatis aislada que comprende una sustitución de aminoácido en Q117, por ejemplo, Q117E, en un marco de lectura abierto de CT849; y una mutación de G216* incorporada en la secuencia de nucléotidos; y/o una sustitución en G322, por ejemplo, G322R, en un marco de lectura abierto de CT389, en donde dicha célula de Chlamydia trachomatis tiene un fenotipo debido a dicha sustitución en Q117 y dicha mutación y/o sustitución en G216 o G322 de patogenicidad atenuada.
MX2017010698A 2015-02-20 2016-02-19 Metodos y composiciones para chlamydia atenuada como vacuna y vector. MX2017010698A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562118961P 2015-02-20 2015-02-20
PCT/US2016/018746 WO2016134300A1 (en) 2015-02-20 2016-02-19 Methods and compositions for attenuated chlamydia as vaccine and vector

Publications (1)

Publication Number Publication Date
MX2017010698A true MX2017010698A (es) 2018-04-30

Family

ID=56689210

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010698A MX2017010698A (es) 2015-02-20 2016-02-19 Metodos y composiciones para chlamydia atenuada como vacuna y vector.
MX2023009696A MX2023009696A (es) 2015-02-20 2017-08-18 Metodos y composiciones para chlamydia atenuada como vacuna y vector.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009696A MX2023009696A (es) 2015-02-20 2017-08-18 Metodos y composiciones para chlamydia atenuada como vacuna y vector.

Country Status (6)

Country Link
US (1) US10596247B2 (es)
EP (1) EP3258961A4 (es)
CA (1) CA2977071A1 (es)
HK (1) HK1248554A1 (es)
MX (2) MX2017010698A (es)
WO (1) WO2016134300A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240156938A1 (en) * 2022-11-10 2024-05-16 Board Of Regents, The University Of Texas System Compositions and methods for treating and preventing human chlamydial infections and diseases using attenuated animal chlamydia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (es) 1968-10-17 1970-08-24
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
EP0442926A1 (en) 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6083702A (en) 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
EP0883344B2 (en) 1995-12-15 2010-06-09 VIRxSYS Corporation Therapeutic molecules generated by trans-splicing
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6623729B2 (en) 2001-07-09 2003-09-23 Korea Advanced Institute Of Science And Technology Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer
ES2312649T3 (es) * 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
AU2003223766A1 (en) 2002-04-30 2003-11-17 University Of North Carolina At Chapel Hill Secretion signal vectors
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
JP4896715B2 (ja) * 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
WO2006029319A2 (en) 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
US20080213759A1 (en) 2005-01-05 2008-09-04 Shionogi & Co., Ltd. Novel Angiogenesis Inhibitor
CN101213203A (zh) 2005-04-29 2008-07-02 教堂山北卡罗莱纳州大学 在转录后水平调节核酸表达的方法和组合物
EP1994043A4 (en) 2006-02-10 2009-05-20 Univ Cincinnati PHOSPHATASE INHIBITOR PROTEIN 1 AS A REGULATOR OF HEART FUNCTION
JP5575486B2 (ja) 2007-01-18 2014-08-20 ユニヴァーシティ オブ ミズーリー−コロンビア 筋鞘にｎＮＯＳを回復させる合成ミニ／ミクロジストロフィン遺伝子
US9068007B2 (en) * 2008-10-09 2015-06-30 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
US20130095487A1 (en) * 2011-10-18 2013-04-18 University Of South Florida Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections

Also Published As

Publication number Publication date
US10596247B2 (en) 2020-03-24
HK1248554A1 (zh) 2018-10-19
WO2016134300A1 (en) 2016-08-25
MX2023009696A (es) 2023-08-28
EP3258961A1 (en) 2017-12-27
US20180021423A1 (en) 2018-01-25
EP3258961A4 (en) 2018-08-22
CA2977071A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2016009072A (es) Fusion de antigenos micobacterianos heterooligomericos.
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
HUE043341T2 (hu) Blautia hydrogenotrophica baktériumtörzset tartalmazó készítmények, hasmenés vagy székrekedés kezelésében vagy megelõzésében történõ alkalmazásra
PH12013502621A1 (en) Vaccine composition comprising an inactivated chikungunya virus strain
MX2019008303A (es) Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika.
BR112019010906A2 (pt) polinucleotídeo, vetor, adenovírus, composição, célula, polipeptídeo, uso dos mesmos, e, métodos para induzir e para elicitar uma resposta imune e para profilaxia ou tratamento em um indivíduo.
PH12018502118B1 (en) Chimeric receptors to flt3 and methods of use thereof
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
MX2017014488A (es) Composiciones para transplante de la flora fecal y metodos para elaborarlos y utilizarlos y dispositivos para suministrarlos.
EA201790550A1 (ru) Способы и композиции для ослабления иммунных ответов к корректирущим ген вирусным трансферным векторам
MX2017011255A (es) Sistema de vector múltiple y sus usos.
GB201212010D0 (en) Formulations
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
EA033538B1 (ru) Композиции и способы усиления иммунного ответа на кишечные патогены
MX2017016401A (es) Composiciones inmunogenas.
WO2016126876A3 (en) Listeria-based adjuvants
MX359302B (es) Composicion para el cuidado de las fibras de queratina y su uso para la limpieza y acondicionamiento de las fibras de queratina.
WO2018035199A8 (en) Sea lice vaccine
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX2023009696A (es) Metodos y composiciones para chlamydia atenuada como vacuna y vector.
MX2018012270A (es) Novedosas formulaciones de vacuna neumococica.
GB2515222A (en) Use of flagellin as a vaccine
PH12017500407A1 (en) Streptococcus agalactiae antigens associated with strains virulent in fish
WO2016134373A3 (en) Leptospira immunoprotective proteins and methods of identification and use thereof